NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

NCT05334472

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Multiple Sclerosis

Interventions: Kesimpta

Countries: United States

This was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Patients with MS Inclusion Criteria:

* Adult aged eighteen (18) years of age or over at the time of the survey
* Prescribed KESIMPTA within the prior 12 months and currently self-administering treatment using the Sensoready® pen
* MS diagnosis based on 2017 McDonald criteria

Care Partner Inclusion Criteria:

* Adult aged eighteen (18) years of age or over
* Formal or informal care partner of patient with MS prescribed KESIMPTA within the prior 12 months
* Is currently administering KESIMPTA using the Sensoready® pen on their patient's behalf

Patients with MS Exclusion Criteria:

* Previously used injection as a part of inclusion in any ofatumumab (OMB) randomized clinical trial
* Active Hepatitis B virus (HBV)
* Cognitive impairment that would impact their ability to participate in a survey study

Locations (1)

East Hanover, New Jersey, United States